Carbamazepine-Implant — Competitive Intelligence Brief

Carbamazepine-Implant (Carbamazepine-Implant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Antiepileptic agent. Area: Neurology.

marketed Anticonvulsant / Antiepileptic agent Voltage-gated sodium channels Neurology Small molecule

Target snapshot

Carbamazepine-Implant (Carbamazepine-Implant) — University of Sao Paulo. Carbamazepine is an anticonvulsant that stabilizes neuronal membranes by blocking sodium channels, reducing repetitive neuronal firing and propagation of seizure activity.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Carbamazepine-Implant TARGET	Carbamazepine-Implant	University of Sao Paulo	marketed	Anticonvulsant / Antiepileptic agent	Voltage-gated sodium channels
Benzocaine oral gel 20%	Benzocaine oral gel 20%	Dina Youssef Attia	marketed	Local anesthetic	Voltage-gated sodium channels
Surgeon-Initiated Local Anesthetic	Surgeon-Initiated Local Anesthetic	University of Wisconsin, Madison	marketed	Local anesthetic	Voltage-gated sodium channels
Intracervical lidocaine	Intracervical lidocaine	Bayero University Kano, Nigeria	marketed	Local anesthetic	Voltage-gated sodium channels
Chloroprocaine 1% Injectable Solution	Chloroprocaine 1% Injectable Solution	Sintetica SA	marketed	Local anesthetic (ester)	Voltage-gated sodium channels
Triamcinolone acetonide-Ketorolac-Ropivacaine	Triamcinolone acetonide-Ketorolac-Ropivacaine	United Health Services Hospitals, Inc.	marketed	Combination injection (corticosteroid + NSAID + local anesthetic)	Glucocorticoid receptor (triamcinolone); COX-1/COX-2 (ketorolac); voltage-gated sodium channels (ropivacaine)
Trileptal®	Trileptal®	Teva Pharmaceuticals USA	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Antiepileptic agent class)

1. University of Sao Paulo · 2 drugs in this class
2. Mario Negri Institute for Pharmacological Research · 2 drugs in this class
3. Janssen Korea, Ltd., Korea · 1 drug in this class
4. Johnson & Johnson Taiwan Ltd · 1 drug in this class
5. Ministry of Health and Sports, Myanmar · 1 drug in this class
6. Odense University Hospital · 1 drug in this class
7. UCB BIOSCIENCES GmbH · 1 drug in this class
8. University Hospitals Cleveland Medical Center · 1 drug in this class
9. Eisai Korea Inc. · 1 drug in this class
10. Upsher-Smith Laboratories · 1 drug in this class